Rhythm Pharmaceuticals (RYTM) Invested Capital (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Invested Capital data on file, last reported at $133.0 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $133.0 million, up 547.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $133.0 million (up 547.79% YoY), and the FY2025 annual result was $146.4 million, up 528.99% from the prior year.
• Invested Capital declined to $133.0 million in Q1 2026 per RYTM's latest filing, from $146.4 million in the prior quarter.
• Over five years, Invested Capital peaked at $354.2 million in Q3 2022 and troughed at -$8.1 million in Q2 2025.
• A 5-year average of $143.2 million and a median of $154.4 million in 2025 frame the typical range for Invested Capital.
• On a YoY basis, Invested Capital climbed as much as 1276.49% in 2025 and fell as far as 120.66% in 2025.
• A 5-year view of Invested Capital shows it stood at $264.3 million in 2022, then tumbled by 35.76% to $169.8 million in 2023, then slumped by 86.29% to $23.3 million in 2024, then surged by 528.99% to $146.4 million in 2025, then slipped by 9.11% to $133.0 million in 2026.
• Business Quant data shows RYTM's Invested Capital at $133.0 million in Q1 2026, $146.4 million in Q4 2025, and $154.4 million in Q3 2025.